Antibodies Recognize and Attack Different SARS-CoV-2 Spike Shapes
ROCKVILLE, MD – The virus that causes COVID-19 belongs to the family of coronaviruses, “corona” referring to the spikes on the viral surface.
Read more
Antibodies
A Cheap, Potent Pathway to Pandemic Therapeutics
By capitalizing on a convergence of chemical, biological and artificial intelligence advances, scientists have developed an unusually fast and efficient method for discovering tiny antibody fragments with big potential for development into therapeutics against deadly diseases.
Read more
Federal COVID-19 response taps UCI Health as a model for delivering monoclonal antibody therapy
Irvine, Calif., Feb. 9, 2021 — Monoclonal antibodies are showing promise for improving outcomes for COVID-19 patients, but when a hospital is already beyond capacity, administering them can be a challenge. As hospitalizations soared across California, clinicians with UCI Health created a system for delivering monoclonal antibodies that is keeping hospital beds available for patients with the greatest need.
Read more
Retrained generic antibodies can recognize SARS-CoV-2
An alternative approach to train the immunity response is offered by researchers at the University of Illinois Chicago and California State University at Sacramento who have developed a novel strategy that redirects antibodies for other diseases existing in humans to the spike proteins of SARS-CoV-2.
Read moreRecruiting Starts at University of Miami Health System for NIH Study of COVID-19 Immunity
The University of Miami Health System is one of five sites nationally and the only one in the Southeast U.S. chosen to participate in a National Institute of Allergy and Infectious Diseases (NIAID) study looking at people who have had COVID-19 or have had a COVID-19 vaccine to examine the durability and robustness of participants’ antibody and T-cell responses to the virus.
Read more
NAU-TGen study results show COVID-19 virus triggers antibodies from previous coronavirus infections
A collaborative study shows COVID-19 virus triggers antibodies from previous coronavirus infections, such as the common cold. It may also explain how previous exposure could partially account for differences in severity between old vs. young patients
Read moreRoyalty Pharma Donates $1,000,000 To Support Mount Sinai’s COVID-19 Patient Care and Clinical Research
Royalty Pharma today announced a charitable contribution by Royalty Pharma in the amount of $1,000,000 to Mount Sinai Health System.
Read more
Antibody cocktails at low doses could be more effective at treating COVID-19, according to new study
Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University in New York. The study, published November 19 in the Journal of Experimental Medicine (JEM), also suggests that in addition to blocking SARS-CoV-2’s entry into cells, the antibodies may combat the virus by enlisting various types of white blood cells to fight the infection.
Read more
COVID-19 Immunity May Last Six Months or More
People who have recovered from coronavirus can make potent antibodies to SARS-CoV-2 that evolve in the months after infection. These antibodies may be evolving in response to residual viral antigen hidden in the gut.
Read more
‘Pinprick’ biomarker blood test offers diagnostic potential for HPV-related cancers – clinical study shows rising antibody levels predict the course of cancer
A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papilloma viruses (HPV) has emerged. It is based on a highly specific diagnostic test that appears to indicate cancer, and predict its course, from just a pinprick of blood.
Read more
Fighting Zika? Call in the T cells
In a new Science Advances study, Shresta and her colleagues at LJI report that the immune system’s T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies.
Read moreTeam assessing if dual-antibody injection prevents COVID-19 illness
A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.
Read more